© 2023 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#Tecentriq

Combination Therapy After Surgery May Delay Liver Cancer Recurrence

Patients who received atezolizumab (Tecentriq) plus bevacizumab (Avastin) had a 28% lower risk of cancer recurrence or death.

FDA Reconsiders Accelerated Approvals of Immunotherapy Drugs

An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.

Checkpoint Inhibitors Improve Outcomes for People With Liver Cancer

Treatment with Tecentriq plus Avastin or with Keytruda alone delays disease progression and improves survival.

FDA Approves Tecentriq Plus Avastin for Liver Cancer

The immunotherapy and targeted therapy combo improved both overall survival and patient-reported outcomes.

Immunotherapy Combo Improves Quality of Life for People With Liver Cancer

Tecentriq plus Avastin improved improved overall survival and patient experiences during treatment.
Advertisement

Hep uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy

Manage

Hep uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.